Pathophysiology

In celiac disease, gliadin peptides from gluten trigger an immune response in genetically predisposed individuals carrying HLA-DQ2 or HLA-DQ8. The reaction damages the small intestinal mucosa, producing villous atrophy, crypt hyperplasia, and intraepithelial lymphocytosis, most prominently in the duodenum. Loss of absorptive surface area causes malabsorption of nutrients, iron, calcium, and fat-soluble vitamins.

Clinical Presentation

The presentation is highly variable. Classic features include chronic diarrhea, steatorrhea, bloating, and weight loss, while many adults present with subtler findings such as iron-deficiency anemia, osteoporosis, or elevated transaminases. In children it can cause failure to thrive. Dermatitis herpetiformis, an intensely itchy vesicular rash, is a specific skin manifestation associated with the disease.

Diagnosis

Testing begins with serology while the patient is still eating gluten: anti-tissue transglutaminase (tTG) IgA is the first-line antibody, with a total IgA level to exclude IgA deficiency. A positive result is confirmed with an upper endoscopy and duodenal biopsy showing villous atrophy. Testing off a gluten-containing diet can produce false negatives, which is a common pitfall.

Management and Complications

The only effective treatment is a strict, lifelong gluten-free diet, which resolves symptoms, heals the mucosa, and normalizes serology over time. Patients are also assessed for nutritional deficiencies and bone density. Untreated or refractory celiac disease carries risks including persistent malabsorption, osteoporosis, and, rarely, enteropathy-associated T-cell lymphoma and small bowel adenocarcinoma.